Treatment group | Â | Days post-treatmenta
|
---|
Day 0 | Day 30 | Day 60 |
---|
Sarolanerb
| # Dogs | 29 | 29 | 28 |
Mean FAD Scoree
| 11.00 | 5.38 | 3.71 |
SD | 8.19 | 4.97 | 4.03 |
Range | 1–30 | 0–21 | 0–15 |
Reduction (%)e
| Â | 51.10 | 66.23 |
Spinosadc
| # Dogs | 26 | 26 | 25 |
Mean FAD Scored
| 13.62 | 6.73 | 5.16 |
SD | 7.42 | 6.51 | 5.17 |
Range | 3–32 | 0–26 | 0–24 |
Reduction (%) | Â | 50.56 | 62.10 |
-
Abbreviation:Â SD standard deviation
-
aIn both groups, dogs were treated on day 0 and once between days 28 – 30
-
bDogs were orally administered Sarolaner chewables (Simparica® Zoetis) according to label directions
-
cDogs were orally administered Spinosad flavored tablets (Comfortis® Elanco) according to label directions
-
dArithmetic mean Flea Allergy Dermatitis lesion score [33]
-
e{(Day 0 arithmetic mean FAD score – day x arithmetic mean FAD score)/day 0 arithmetic mean FAD score)} × 100
- No significant differences between the two groups were observed, for any day, based on the repeated measures analysis (PÂ =Â 0.2086)